Valneva Stock Performance and Market Overview
- Valneva (VLA.PA)
- Trading price as of 12:50 PM Central Europe on Friday 23 Oct 2026: EUR 2.40.
- Shares traded in the last 24 hours: EUR 914.9 k.
- Current market capitalization: EUR 469.1 mn.
- Share supply: 189.8 mn.
- Daily change: ‑1.75 %.
- Monthly change (from end of last month): ‑12.68 %.
- Simple moving average (200 days): EUR 2.99.
- 52‑week high: EUR 5.15 (25 Feb 2026).
- 52‑week low: EUR 2.03 (24 Jul 2026).
Related Stock Performance (Last 24 Hours)
| Ticker | Current Price (EUR) | Market Cap (EUR mn) | 24‑hr Change | P/E Ratio |
|---|---|---|---|---|
| Elior (ELIOR.PA) | 1.78 | 490.5 | +0.11 % | 6.91 |
| Genfit (GNFT.PA) | 8.73 | 504.6 | +3.00 % | – |
| Idi (IDIP.PA) | 65.4 | 520.2 | +0.91 % | 4.58 |
| Oeneo (SBT.PA) | 8.74 | 548.8 | 0.00 % | 21.3 |
| Bassac (BASS.PA) | 33.8 | 559.0 | +3.57 % | 5.4 |
Company Overview – Valneva SE
Valneva SE is a French biotechnology company focused on developing and commercializing vaccines for infectious diseases. Key products include:
- IXIARO/JESPECT – vaccine for Japanese encephalitis.
- Dukoral – vaccine for cholera and enterotoxigenic E. coli diarrhea in travelers.
Ongoing research targets vaccines for Clostridium difficile, Lyme disease, chikungunya, and Zika virus. The company utilizes its proprietary EB66 vaccine production cell line and IC31 adjuvant technology.
Valneva operates globally and is headquartered in Nantes, France. Its shares trade on NYSE Euronext Paris and are listed on the NYSE Euronext Paris. The company conducted its initial public offering on 29 June 2007.
For further information, visit the company website at www.valneva.com .
